HER2-IN-22

HER2-IN-22 (also known as Compound 3f) is an experimental preclinical small molecule inhibitor belonging to the pyrazolopyridine chemical class. Developed through academic research, this agent was synthesized using a novel green one-pot method and functions as a selective inhibitor of the Human Epidermal Growth Factor Receptor 2 (HER2) kinase. In preclinical biochemical assays, it demonstrated potency comparable to the FDA-approved inhibitor tucatinib. HER2-IN-22 has been shown to induce apoptosis in HER2-positive breast cancer cell lines, such as BT474, and has exhibited significant antitumor activity in breast cancer xenograft mouse models, reducing tumor size by approximately 19.45%. Its development remains in the preclinical phase, primarily targeting HER2-positive breast cancer.

Other names

Compound 3fCompound3fCompound-3fpyrazolopyridine-congener 3fpyrazolopyridine-congener3fpyrazolopyridine-congener-3f